PDF herunterladen
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2019; 79(07): 705-712
DOI: 10.1055/a-0882-3791
GebFra Science
Original Article
Georg Thieme Verlag KG Stuttgart · New York

The Effect of Dehydroepiandrosterone (DHEA) Supplementation on IVF or ICSI: A Meta-Analysis of Randomized Controlled Trials

Auswirkungen der Dehydroepiandrosteron-(DHEA-)Supplementierung auf IVF oder ICSI: eine Metaanalyse von randomisierten kontrollierten Studien
Lin Xu
1   Department of reproductive medicine, First Affiliated Hospital of Hainan Medical College, Haikou, Hainan 570102, China
,
Chunxia Hu
2   Department of Obstetrics, First Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570102, China
,
Qun Liu
1   Department of reproductive medicine, First Affiliated Hospital of Hainan Medical College, Haikou, Hainan 570102, China
,
Yaxuan Li
1   Department of reproductive medicine, First Affiliated Hospital of Hainan Medical College, Haikou, Hainan 570102, China
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 04. Januar 2019
revised 20. März 2019

accepted 22. März 2019

Publikationsdatum:
10. Juli 2019 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Introduction A systematic review and meta-analysis were conducted to evaluate the efficacy of dehydroepiandrosterone (DHEA) supplementation in patients with diminished ovarian reserve (DOR) and/or poor ovarian response (POR) who were undergoing in vitro fertilization or intracytoplasmic sperm injection (IVF/ICSI).

Patients and Methods We searched the PubMed, EMBASE, Web of Science, and Cochrane Library electronic databases for literature published until July 2018. The analysis included randomized controlled trials (RCTs) of the effects of DHEA versus placebo on IVF or ICSI. Two independent reviewers extracted information from the reports and evaluated the quality of the studies. Overall, we identified nine prospective RCTs involving 833 patients.

Results Compared to the controls, patients treated with DHEA exhibited increases in the number of retrieved oocytes (mean difference, 0.91; 95% confidence interval [CI], 0.23 – 1.59; p = 0.009), clinical pregnancy rate (relative risk [RR] = 1.27; 95% CI, 1.01 – 1.61; p = 0.04), and live birth rate (RR, 1.76; 95% CI, 1.17 – 2.63; p = 0.006). However, there was no intergroup difference in the miscarriage rate (RR, 0.37; 95% CI, 0.12 – 1.13; p = 0.08).

Conclusion DHEA supplementation improved the outcomes of IVF/ICSI in women with DOR or POR.

Zusammenfassung

Einleitung Es wurde eine systematische Überprüfung und eine Metaanalyse durchgeführt, um die Wirksamkeit der Dehydroepiandrosterone-(DHEA-)Supplementierung zu bewerten bei Patientinnen mit eingeschränkter ovarieller Reserve (DOR) und/oder unzureichender ovarieller Reaktion (POR), die sich einer In-vitro-Fertilisation bzw. einer intrazytoplasmatischen Spermieninjektion (IVF/ICSI) unterzogen.

Patientinnen und Methoden In einer Literaturrecherche wurde in den elektronischen Datenbanken von PubMed, EMBASE, Web of Science und der Cochrane Library nach Literatur gesucht, die vor Juli 2018 zu diesem Thema veröffentlicht worden war. In die Analyse aufgenommen wurden randomisierte kontrollierte Studien (RCTs), welche die Auswirkungen von DHEA auf IVF und ICSI mit Placebo verglichen. Die Studiendaten wurden von 2 unabhängigen Beurteilern gesammelt, die auch die Qualität der jeweiligen Studien evaluierten. Insgesamt konnten wir 9 prospektive RCTs mit insgesamt 833 Patientinnen ausfindig machen.

Ergebnisse Verglichen mit den jeweiligen Kontrollgruppen, nahm bei den mit DHEA behandelten Patientinnen die Anzahl gewonnener Eizellen zu (Mittelwertdifferenz, 0,91; 95%-Konfidenzintervall [KI], 0,23 – 1,59; p = 0,009); die klinische Schwangerschaftsrate (relatives Risiko [RR] = 1,27; 95%-KI, 1,01 – 1,61; p = 0,04) und die Lebendgeburtenrate (RR, 1,76; 95%-KI, 1,17 – 2,63; p = 0,006) nahmen ebenfalls zu. Es gab aber keine Differenz zwischen den Gruppen in Bezug auf die Fehlgeburtenrate (RR, 0,37; 95%-KI, 0,12 – 1,13; p = 0,08).

Schlussfolgerung Die DHEA-Supplementierung trug zu einer Verbesserung des Outcomes nach IVF/ICSI bei Frauen mit DOR oder POR bei.

Key words

dehydroepiandrosterone (DHEA) - diminished ovarian reserve (DOR) - poor ovarian response (POR) - in vitro fertilization (IVF) - intracytoplasmic sperm injection (ICSI)

Schlüsselwörter

Dehydroepiandrosteron (DHEA) - eingeschränkte ovarielle Reserve (DOR) - schlechte ovarielle Reaktion (POR) - In-vitro-Fertilisation (IVF) - intrazytoplasmatische Spermieninjektion (ICSI)
 

  • References

  • 1 Gnoth C, Godehardt E, Frank-Herrmann P. et al. Definition and prevalence of subfertility and infertility. Hum Reprod 2005; 20: 1144-1147
    CrossrefPubMedGoogle Scholar
  • 2 Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009; 30: 465-493
    CrossrefPubMedGoogle Scholar
  • 3 Fouany MR, Sharara FI. Is there a role for DHEA supplementation in women with diminished ovarian reserve?. J Assist Reprod Genet 2013; 30: 1239-1244
    CrossrefPubMedGoogle Scholar
  • 4 Broekmans FJ, Kwee J, Hendriks DJ. et al. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006; 12: 685-718
    CrossrefPubMedGoogle Scholar
  • 5 Broekmans FJ, Faddy MJ, Scheffer G. et al. Antral follicle counts are related to age at natural fertility loss and age at menopause. Menopause 2004; 11: 607-614
    CrossrefPubMedGoogle Scholar
  • 6 Santoro N, Isaac B, Neal-Perry G. et al. Impaired folliculogenesis and ovulation in older reproductive aged women. J Clin Endocrinol Metab 2003; 88: 5502-5509
    CrossrefPubMedGoogle Scholar
  • 7 Soules MR, Sherman S, Parrott E. et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001; 76: 874-878
    CrossrefPubMedGoogle Scholar
  • 8 Templeton A, Morris JK, Parslow W. Factors that affect outcome of in-vitro fertilisation treatment. Lancet 1996; 348: 1402-1406
    CrossrefPubMedGoogle Scholar
  • 9 Menken J, Trussell J, Larsen U. Age and infertility. Science 1986; 233: 1389-1394
    CrossrefPubMedGoogle Scholar
  • 10 Gleicher N, Weghofer A, Barad DH. Defining ovarian reserve to better understand ovarian aging. Reprod Biol Endocrinol 2011; 9: 23
    CrossrefPubMedGoogle Scholar
  • 11 Trout SW, Seifer DB. Do women with unexplained recurrent pregnancy loss have higher day 3 serum FSH and estradiol values?. Fertil Steril 2000; 74: 335-337
    CrossrefPubMedGoogle Scholar
  • 12 Ulug U, Ben-Shlomo I, Turan E. et al. Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles. Reprod Biomed Online 2003; 6: 439-443
    CrossrefPubMedGoogle Scholar
  • 13 Surrey ES, Schoolcraft WB. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril 2000; 73: 667-676
    CrossrefPubMedGoogle Scholar
  • 14 Tarlatzis BC, Zepiridis L, Grimbizis G. et al. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update 2003; 9: 61-76
    CrossrefPubMedGoogle Scholar
  • 15 Burger HG. Androgen production in women. Fertil Steril 2002; 77 (Suppl. 04) S3-S5
    PubMedGoogle Scholar
  • 16 Casson PR, Lindsay MS, Pisarska MD. et al. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod 2000; 15: 2129-2132
    CrossrefPubMedGoogle Scholar
  • 17 Triantafyllidou O, Sigalos G, Vlahos N. Dehydroepiandrosterone (DHEA) supplementation and IVF outcome in poor responders. Hum Fertil (Camb) 2017; 20: 80-87
    CrossrefPubMedGoogle Scholar
  • 18 Qin JC, Fan L, Qin AP. The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evidence from a meta-analysis. J Gynecol Obstet Hum Reprod 2017; 46: 1-7
    PubMedGoogle Scholar
  • 19 Zhang M, Niu W, Wang Y. et al. Dehydroepiandrosterone treatment in women with poor ovarian response undergoing IVF or ICSI: a systematic review and meta-analysis. J Assist Reprod Genet 2016; 33: 981-991
    CrossrefPubMedGoogle Scholar
  • 20 Zhang J, Qiu X, Gui Y. et al. Dehydroepiandrosterone improves the ovarian reserve of women with diminished ovarian reserve and is a potential regulator of the immune response in the ovaries. Biosci Trends 2015; 9: 350-359
    CrossrefPubMedGoogle Scholar
  • 21 Li J, Yuan H, Chen Y. et al. A meta-analysis of dehydroepiandrosterone supplementation among women with diminished ovarian reserve undergoing in vitro fertilization or intracytoplasmic sperm injection. Int J Gynaecol Obstet 2015; 131: 240-245
    CrossrefPubMedGoogle Scholar
  • 22 Nagels HE, Rishworth JR, Siristatidis CS. et al. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev 2015; (11) CD009749
    PubMedGoogle Scholar
  • 23 Urman B, Yakin K. Does dehydroepiandrosterone have any benefit in fertility treatment?. Curr Opin Obstet Gynecol 2012; 24: 132-135
    CrossrefPubMedGoogle Scholar
  • 24 Sunkara SK, Pundir J, Khalaf Y. Effect of androgen supplementation or modulation on ovarian stimulation outcome in poor responders: a meta-analysis. Reprod Biomed Online 2011; 22: 545-555
    CrossrefPubMedGoogle Scholar
  • 25 Higgins JP, Altman DG, Gotzsche PC. et al. The Cochrane Collaborationʼs tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
    CrossrefPubMedGoogle Scholar
  • 26 Narkwichean A, Maalouf W, Baumgarten M. et al. Efficacy of Dehydroepiandrosterone (DHEA) to overcome the effect of ovarian ageing (DITTO): A proof of principle double blinded randomized placebo controlled trial. Eur J Obstet Gynecol Reprod Biol 2017; 218: 39-48
    CrossrefPubMedGoogle Scholar
  • 27 Kotb MM, Hassan AM, AwadAllah AM. Does dehydroepiandrosterone improve pregnancy rate in women undergoing IVF/ICSI with expected poor ovarian response according to the Bologna criteria? A randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2016; 200: 11-15
    CrossrefPubMedGoogle Scholar
  • 28 Tartagni M, Cicinelli MV, Baldini D. et al. Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old. Reprod Biol Endocrinol 2015; 13: 18
    CrossrefPubMedGoogle Scholar
  • 29 Zhang HH, Xu PY, Wu J. et al. Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing in vitro fertilization: a randomized controlled trial. J Ovarian Res 2014; 7: 93
    CrossrefPubMedGoogle Scholar
  • 30 Yeung TW, Chai J, Li RH. et al. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertil Steril 2014; 102: 108-115.e1
    CrossrefPubMedGoogle Scholar
  • 31 Kara M, Aydin T, Aran T. et al. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve?. Eur J Obstet Gynecol Reprod Biol 2014; 173: 63-65
    CrossrefPubMedGoogle Scholar
  • 32 Moawad A, Shaeer M. Long-term androgen priming by use of dehydroepiandrosterone (DHEA) improves IVF outcome in poor-responder patients. A randomized controlled study. Middle East Fertil Soc J 2012; 17: 268-274
    CrossrefPubMedGoogle Scholar
  • 33 Artini PG, Simi G, Ruggiero M. et al. DHEA supplementation improves follicular microenviroment in poor responder patients. Gynecol Endocrinol 2012; 28: 669-673
    CrossrefPubMedGoogle Scholar
  • 34 Wiser A, Gonen O, Ghetler Y. et al. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod 2010; 25: 2496-2500
    CrossrefPubMedGoogle Scholar
  • 35 Narkwichean A, Maalouf W, Campbell BK. et al. Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis. Reprod Biol Endocrinol 2013; 11: 44
    CrossrefPubMedGoogle Scholar
  • 36 Barad DH, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril 2005; 84: 756
    PubMedGoogle Scholar
  • 37 Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 2006; 21: 2845-2849
    CrossrefPubMedGoogle Scholar
  • 38 Gleicher N, Ryan E, Weghofer A. et al. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod Biol Endocrinol 2009; 7: 108
    CrossrefPubMedGoogle Scholar
  • 39 Sonmezer M, Ozmen B, Cil AP. et al. Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders. Reprod Biomed Online 2009; 19: 508-513
    CrossrefPubMedGoogle Scholar
  • 40 Harper AJ, Buster JE, Casson PR. Changes in adrenocortical function with aging and therapeutic implications. Semin Reprod Endocrinol 1999; 17: 327-338
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 41 Gleicher N, Kim A, Weghofer A. et al. Hypoandrogenism in association with diminished functional ovarian reserve. Hum Reprod 2013; 28: 1084-1091
    CrossrefPubMedGoogle Scholar
  • 42 Hillier SG, Whitelaw PF, Smyth CD. Follicular oestrogen synthesis: the ‘two-cell, two-gonadotrophin’ model revisited. Mol Cell Endocrinol 1994; 100: 51-54
    CrossrefPubMedGoogle Scholar
  • 43 Casson PR, Santoro N, Elkind-Hirsch K. et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil Steril 1998; 70: 107-110
    CrossrefPubMedGoogle Scholar
  • 44 Arlt W, Callies F, van Vlijmen JC. et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999; 341: 1013-1020
    CrossrefPubMedGoogle Scholar